Warfarin induced Ovarian Haematoma Mimicking Torsion Ovarian Tumour

2020 ◽  
Vol 7 (2) ◽  
pp. 01-05
Author(s):  
Paapa Dasari
Keyword(s):  
Heart Disease ◽  
Mitral Valve ◽  
Adnexal Mass ◽  
Ovarian Tumour ◽  
Dose Titration ◽  
Doppler Flow ◽  
Pain Abdomen ◽  
International Normalised Ratio ◽  
History Of ◽  
Rheumatic Heart

Warfarin toxicity presenting as acute abdomen in a woman with chronic anticoagulation is rare. A 29 year old woman with Rheumatic heart disease with history of  mitral Valve replacement who was on anticoagulation with warfarin presented with pain abdomen  of 2 weeks duration and she was  clinically diagnosed as torsion ovarian cyst. On USG abdomen there was a complex adnexal mass of 6x8 cms with Doppler flow. Her International Normalised Ratio was more than 10 and hence a diagnosis of Ovarian haematoma was entertained and she was managed medically with dose titration of anticoagulants and her pain abdomen subsided and she was discharged home after normalising her International normalised ratio and laparotomy was thus avoided.

scholarly journals Controlled Trial of Sulfinpyrazone in Rheumatic Heart Disease. Preliminary Results

1977 ◽  
Author(s):  
Peter Steele ◽  
Joseph Rainwater ◽  
Edward Genton
Keyword(s):  
Heart Disease ◽  
Mitral Valve ◽  
Survival Time ◽  
Rheumatic Heart Disease ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Controlled Trial ◽  
Preliminary Results ◽  
History Of ◽  
Rheumatic Heart

Platelet survival time (SURV) has correlated with a history of thromboembolism (TE) in patients with rheumatic heart disease (RHD). A controlled trial of sulfinpyrazone (SFP) in RHD is in progress and 138 patients have been entered. SURV (51Chromium labelling) was shortened (2.3 ± 0.08 days; AVE t 1/2 ± SEM; normal 3.7 ± 0.04 days) in 40 of 41 (98%) with a history of TE and in 76 of 97 (78%) (2.9 ± 0.07 days; P<0.001) of those without a history of TE. One hundred sixteen with shortened SURV have been randomized to SFP or placebo and 67 have either completed four years (N=37), undergone mitral valve replacement (N=18) (ave 19 months; range 6-32 months), had definite TE (N=8) (average 14 months; range 8-23 months) or died (N=4) (average 15 months; range 5-22 months). Definite TE (prolonged neurologic deficit) occurred in one on SFP and in seven on placebo (all with shortened SURV) (X2 = 4.31; NS). SFP increased SURV (2.4 ± 0.12 to 2.7 ± 0.13 days; N=23; P<0.001) and 12 (52%) had an increase in SURV of >0.02 days. The patient on SFP with new TE had no change in SURV (2.3 to 2.3 days). Placebo did not alter SURV (2.4 ± 0.15 to 2.5 ± 0.08 days; N=26; NS) and two (8%) had an alteration of SURV by > 0.02 days. SURV was not altered in patients with normal SURV (3.7 ± 0.08 to 3.6 ± 0.08 days; N=12; NS) and no patient with normal SURV has had shortened SURV on subsequent yearly measurement. Patients with normal SURV were not randomized. Results suggest that SURV is shortened in patients with RHD who have had or will have TE, that SFP increases SURV and may prevent TE in these patients.

The variable spectrum of anterior mitral valve leaflet restriction in rheumatic heart disease screening

2021 ◽  
Author(s):  
Luke David Hunter ◽  
Anton F. Doubell ◽  
Alfonso J. K. Pecoraro ◽  
Mark Monaghan ◽  
Guy Lloyd ◽  
...  
Keyword(s):  
Heart Disease ◽  
Mitral Valve ◽  
Rheumatic Heart Disease ◽  
Disease Screening ◽  
Valve Leaflet ◽  
Mitral Valve Leaflet ◽  
Rheumatic Heart

R15 Long-term Outcome Following Mitral Valve Repair in Rheumatic Heart Disease

2021 ◽  
Vol 30 ◽  
pp. S21-S22
Author(s):  
K.F.L. Lee ◽  
O.J.O.J. Lee ◽  
T.L.D. Chan ◽  
K.L.C. Ho ◽  
W.K.T. Au
Keyword(s):  
Heart Disease ◽  
Mitral Valve ◽  
Rheumatic Heart Disease ◽  
Mitral Valve Repair ◽  
Valve Repair ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Rheumatic Heart

Giant left atrium in a woman with mitral prosthetic valve malfunction and history of rheumatic heart disease

2009 ◽  
Vol 4 (5) ◽  
pp. 435-437
Author(s):  
Gaspare Parrinello ◽  
Daniele Torres ◽  
Salvatore Paterna ◽  
Manuela Mezzero ◽  
Pietro Di Pasquale ◽  
...  
Keyword(s):  
Heart Disease ◽  
Left Atrium ◽  
Rheumatic Heart Disease ◽  
Prosthetic Valve ◽  
History Of ◽  
Giant Left Atrium ◽  
Valve Malfunction ◽  
Rheumatic Heart

Optimising echocardiographic screening for rheumatic heart disease in New Zealand: not all valve disease is rheumatic

2011 ◽  
Vol 21 (4) ◽  
pp. 436-443 ◽  
Author(s):  
Rachel H. Webb ◽  
Nigel J. Wilson ◽  
Diana R. Lennon ◽  
Elizabeth M. Wilson ◽  
Ross W. Nicholson ◽  
...  
Keyword(s):  
Heart Disease ◽  
New Zealand ◽  
High Risk ◽  
Mitral Valve ◽  
Rheumatic Heart Disease ◽  
Secondary Prophylaxis ◽  
Accurate Diagnosis ◽  
High Risk Population ◽  
Step Model ◽  
Rheumatic Heart

AbstractAimsEchocardiography detects a greater prevalence of rheumatic heart disease than heart auscultation. Echocardiographic screening for rheumatic heart disease combined with secondary prophylaxis may potentially prevent severe rheumatic heart disease in high-risk populations. We aimed to determine the prevalence of rheumatic heart disease in children from an urban New Zealand population at high risk for acute rheumatic fever.Methods and resultsTo optimise accurate diagnosis of rheumatic heart disease, we utilised a two-step model. Portable echocardiography was conducted on 1142 predominantly Māori and Pacific children aged 10–13 years. Children with an abnormal screening echocardiogram underwent clinical assessment by a paediatric cardiologist together with hospital-based echocardiography. Rheumatic heart disease was then classified asdefinite, probable, orpossible. Portable echocardiography identified changes suggestive of rheumatic heart disease in 95 (8.3%) of 1142 children, which reduced to 59 (5.2%) after cardiology assessment. The prevalence ofdefiniteandprobablerheumatic heart disease was 26.0 of 1000, with 95% confidence intervals ranging from 12.6 to 39.4. Portable echocardiography overdiagnosed rheumatic heart disease with physiological valve regurgitation diagnosed in 28 children. A total of 30 children (2.6%) had non-rheumatic cardiac abnormalities, 11 of whom had minor congenital mitral valve anomalies.ConclusionsWe found high rates of undetected rheumatic heart disease in this high-risk population. Rheumatic heart disease screening has resource implications with cardiology evaluation required for accurate diagnosis. Echocardiographic screening for rheumatic heart disease may overdiagnose rheumatic heart disease unless congenital mitral valve anomalies and physiological regurgitation are excluded.

scholarly journals Mitral Valve Replacement in Children and Adolescents with Rheumatic Heart Disease

1976 ◽  
Vol 17 (5) ◽  
pp. 570-579 ◽  
Author(s):  
Stanley JOHN ◽  
Susil MUNSI ◽  
I. P. SUKUMAR ◽  
George CHERIAN
Keyword(s):  
Heart Disease ◽  
Mitral Valve ◽  
Children And Adolescents ◽  
Rheumatic Heart Disease ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Rheumatic Heart

scholarly journals Validation of a simplified score for predicting latent rheumatic heart disease progression using a prospective cohort of Brazilian schoolchildren

BMJ Open ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. e036827 ◽  
Author(s):  
Bárbara Martins Bechtlufft ◽  
Bruno Ramos Nascimento ◽  
Craig Sable ◽  
Clara Leal Fraga ◽  
Márcia Melo Barbosa ◽  
...  
Keyword(s):  
Heart Disease ◽  
Public Schools ◽  
Rheumatic Heart Disease ◽  
Heart Diseases ◽  
Diagnostic Category ◽  
Secondary Outcome ◽  
Unfavourable Outcome ◽  
History Of ◽  
Rheumatic Heart

ObjectivesEchocardiographic (echo) screening is an important tool to estimate rheumatic heart disease (RHD) prevalence, but the natural history of screen-detected RHD remains unclear. The PROVAR+ (Programa de RastreamentO da VAlvopatia Reumática) study, which uses non-experts, telemedicine and portable echo, pioneered RHD screening in Brazil. We aimed to assess the mid-term evolution of Brazilian schoolchildren (5–18 years) with echocardiography-detected subclinical RHD and to assess the performance of a simplified score consisting of five components of the World Heart Federation criteria, as a predictor of unfavourable echo outcomes.SettingPublic schools of underserved areas and private schools in Minas Gerais, southeast Brazil.ParticipantsA total of 197 patients (170 borderline and 27 definite RHD) with follow-up of 29±9 months were included. Median age was 14 (12–16) years, and 130 (66%) were woman. Only four patients in the definite group were regularly receiving penicillin.Primary and secondary outcome measuresUnfavourable outcome was based on the 2-year follow-up echo, defined as worsening diagnostic category, remaining with mild definite RHD or development/worsening of valve regurgitation/stenosis.ResultsAmong patients with borderline RHD, 29 (17.1%) progressed to definite, 49 (28.8%) remained stable, 86 (50.6%) regressed to normal and 6 (3.5%) were reclassified as other heart diseases. Among those with definite RHD, 13 (48.1%) remained in the category, while 5 (18.5%) regressed to borderline, 5 (18.5%) regressed to normal and 4 (14.8%) were reclassified as other heart diseases. The simplified echo score was a significant predictor of RHD unfavourable outcome (HR 1.197, 95% CI 1.098 to 1.305, p<0.001).ConclusionThe simple risk score provided an accurate prediction of RHD status at 2-year follow-up, showing a good performance in Brazilian schoolchildren, with a potential value for risk stratification and monitoring of echocardiography-detected RHD.

scholarly journals A meta-analysis of late outcomes of mitral valve repair in patients with rheumatic heart disease

2017 ◽  
Vol 9 (11) ◽  
pp. 4366-4375 ◽  
Author(s):  
Jin-Tao Fu ◽  
Mohammad Sharif Popal ◽  
Hai-Bo Zhang ◽  
Wei Han ◽  
Qiu-Ming Hu ◽  
...  
Keyword(s):  
Heart Disease ◽  
Mitral Valve ◽  
Rheumatic Heart Disease ◽  
Mitral Valve Repair ◽  
Meta Analysis ◽  
Valve Repair ◽  
Rheumatic Heart
Sign in / Sign up

Export Citation Format

Share Document